Bimagrumab plus a GLP-1 drug is the most ambitious answer yet to one of the uncomfortable truths of the obesity drug boom: when patients lose weight on semaglutide or tirzepatide, roughly a quarter to 40 percent of the weight they lose is lean mass, including skeletal muscle. Eli Lilly has bet up to $1.925 billion on the thesis that the next generation of obesity therapy will not just produce more weight loss — it will produce cleaner weight loss, shifting the ratio toward pure fat burning while protecting muscle. Bimagrumab is the lead candidate for that combination strategy, and the BELIEVE trial is the flagship clinical program meant to validate it.
⚕️ Regulatory notice: Bimagrumab is investigational for obesity. It was previously studied in other indications (inclusion body myositis, sarcopenia) and did not reach approval in those settings. Combination trials with GLP-1 agonists are ongoing as of 2026. Nothing in this article is medical advice.
What Is Bimagrumab?
Bimagrumab is a fully human monoclonal antibody — not a peptide — that binds and blocks the activin type II receptor (ActRII). ActRII is the receptor through which myostatin, activin A, and several related ligands signal to muscle tissue. Myostatin is the body's primary brake on skeletal muscle growth: when you block myostatin signaling, muscle mass increases.
Bimagrumab is included in our peptide coverage despite being an antibody because it sits at the heart of the peptide obesity story. Every major GLP-1 developer is now thinking about how to either pair their peptide with an antibody like bimagrumab or replace it with a next-generation myostatin-targeting peptide that achieves similar effects through a different modality.
The drug's history is winding:
- Novartis originally developed bimagrumab for sporadic inclusion body myositis (sIBM), a rare muscle-wasting disease. It failed Phase 3 in that indication in 2016.
- Novartis subsequently tested it in sarcopenia with mixed results.
- The asset was out-licensed to Versanis Bio, a specialist biotech that repositioned bimagrumab for obesity and cardiometabolic disease, explicitly targeting the lean-mass problem.
- In July 2023, Eli Lilly acquired Versanis in a deal worth up to $1.925 billion including milestones — a price that only makes sense if you view bimagrumab as a key strategic asset for the obesity franchise, not a standalone product.
For context on the broader concern, see our article on GLP-1 drugs and muscle loss, which walks through why sarcopenia is a real clinical concern for long-term GLP-1 users.
Mechanism: Blocking the Activin Receptor
Skeletal muscle growth is tightly regulated by a network of TGF-β superfamily ligands. The most famous is myostatin (GDF-8), the protein mutations of which produce the famously over-muscled Belgian Blue cattle and the occasional "super-strong" human case. Myostatin binds ActRIIB, which signals through Smad2/3 to suppress muscle protein synthesis.
Bimagrumab binds ActRII (both A and B isoforms) and blocks the interaction between the receptor and its ligands — myostatin, activin A, and related factors. The effect is a release of the brake:
- Skeletal muscle mass increases (several kilograms over months in clinical studies).
- Fat mass decreases — notably, bimagrumab also produces fat loss on its own, likely via a mix of metabolic rewiring and improved glucose disposal in the expanded muscle compartment.
- Insulin sensitivity improves, consistent with the muscle-as-glucose-sink mechanism.
Against this backdrop, the rationale for combining with a GLP-1 is straightforward. GLP-1 drugs produce large-magnitude weight loss but with unwanted lean-mass loss. Bimagrumab produces modest fat loss plus muscle gain. Together, they should produce equivalent or greater total weight loss with a much higher proportion of fat, leaving patients leaner in the literal sense.
Evidence and Clinical Trials
Phase 2 Monotherapy in Obesity — Heymsfield et al., JAMA 2021
A pivotal early signal came from a 2021 JAMA Network Open study led by Steven Heymsfield and Versanis collaborators. In adults with obesity and type 2 diabetes, bimagrumab administered every four weeks for 48 weeks produced:
- Body fat reduction of ~20.5 percent (versus a modest increase on placebo).
- Lean mass increase of ~3.6 percent.
- HbA1c reduction comparable to some first-generation diabetes drugs.
Those numbers are modest compared with GLP-1 agonists in raw weight-loss terms, but the compositional shift — losing fat while gaining muscle — was unlike anything GLP-1s could do. That result is what made Versanis, and later Lilly, willing to bet on combination trials.
BELIEVE Phase 2 — Bimagrumab + Semaglutide
The BELIEVE study (NCT05616013) is the flagship combination trial, testing bimagrumab with semaglutide in adults with obesity. The design compares semaglutide alone, bimagrumab alone, and the combination across body composition endpoints (DEXA-measured fat mass, lean mass, total body weight). The central hypothesis: the combination will produce equivalent or greater total weight loss versus semaglutide alone while protecting lean mass.
Topline readouts from 2024–2025 interim data, widely reported at conferences, showed:
- Fat mass loss: Substantially greater with the combination than with either agent alone.
- Lean mass: Preserved or gained with the combination, compared with lean mass loss on semaglutide monotherapy.
- Total weight loss: At least matching, and in some analyses exceeding, semaglutide alone.
These are exactly the results that justified the $1.925 billion Versanis acquisition, and Lilly has signaled continued investment in combination programs with both semaglutide and its own tirzepatide and retatrutide.
Broader Evidence Base
Earlier bimagrumab trials in sarcopenia (Rooks et al., 2017) and inclusion body myositis (Amato et al., 2014–2016) did not show clinical benefit on function in those populations despite producing measurable muscle mass gains. That disconnect is a cautionary note: adding muscle mass is not the same as adding muscle function. For obesity, the goal is metabolic and aesthetic — a different endpoint than the functional improvement sought in sIBM — so the prior failures may not predict obesity outcomes. But the distinction matters.
The Strategic Story
The $1.925 billion Versanis deal was unusual. Lilly was not paying for a late-stage asset with imminent approval. It was paying for a strategic piece in the obesity arms race. The logic:
- The lean-mass problem is becoming a public narrative. Media coverage of "Ozempic face," muscle loss, and frailty risk in older GLP-1 users is reshaping physician and patient attitudes.
- Combination therapy will define the next generation. Just as HIV moved from monotherapy to combination regimens, obesity pharmacology is heading toward multi-agent protocols. Whoever owns the muscle-preservation component of those protocols owns a large share of the market.
- Peptide competitors are coming. Several biotechs are developing myostatin-targeting peptides that could achieve similar biology with easier manufacturing, including Regeneron's REGN1033 and earlier-stage assets from Scholar Rock and others. By acquiring bimagrumab, Lilly secured the most clinically advanced asset in the category.
- Defensive positioning. If Novo Nordisk or another competitor had acquired Versanis, Lilly's obesity franchise would have faced a differentiated opponent. Owning the asset eliminates that risk.
Connection to the Broader Peptide Ecosystem
Bimagrumab is technically an antibody, but its role in the obesity story belongs squarely inside the peptide and metabolic-disease ecosystem. The broader trend is a shift from weight-loss drugs to body-composition drugs. The questions physicians and patients are starting to ask are no longer just "how many pounds?" but "how much fat? how much muscle? how much function?"
That reframing has several downstream effects:
- Myostatin-targeting peptides become attractive development targets. Smaller, cheaper, easier-to-scale than antibodies, they could unlock broader access to muscle-preservation strategies.
- DEXA scan uptake is increasing in clinical trials and in obesity clinics, as body-composition endpoints take precedence over scale weight.
- Sarcopenia-as-disease gains regulatory momentum. Muscle loss in older adults has been clinically under-recognized; the obesity-drug era is pushing it back onto the radar.
- Combination pricing and access become policy issues. A bimagrumab-plus-tirzepatide regimen could easily exceed $30,000 per year, raising new questions about who pays and who benefits.
See our coverage of GLP-1 and muscle loss for the full clinical picture of why this matters.
Limitations and Lessons
- Prior failures in myositis and sarcopenia. Bimagrumab has added muscle mass before without adding function in those settings. Whether the obesity setting is different remains to be proven.
- Antibody manufacturing and cost. Monoclonal antibodies are expensive to produce relative to peptides. A combination regimen adds that cost on top of GLP-1 cost.
- Long-term safety. Chronic ActRII blockade has theoretical risks — effects on the reproductive axis, bone, and hematopoiesis. Long-term data are limited.
- Injection burden. Bimagrumab is dosed every four weeks, so it adds an additional injection to a GLP-1 regimen. Patient acceptance of two injectables is unknown.
- Regulatory path uncertainty. Obesity has clear endpoints, but "muscle preservation" as a labeled claim requires specific study designs and regulatory negotiation. Getting the label right will matter more than the biology.
FAQ
Is bimagrumab a peptide?
No. Bimagrumab is a monoclonal antibody targeting the activin type II receptor. It is included in peptide-therapeutics coverage because of its role in GLP-1 combination strategies and because next-generation myostatin-targeting peptides aim for similar biology.
Why does muscle loss matter when taking GLP-1 drugs?
Roughly 25 to 40 percent of the weight lost on GLP-1 drugs comes from lean mass, including skeletal muscle. Muscle loss is associated with weakness, falls, metabolic dysfunction, and loss of independence — particularly in older adults. See our article on GLP-1 and muscle loss.
How does bimagrumab work?
It blocks the activin type II receptor, removing the brake that myostatin and related ligands place on skeletal muscle growth. The result is increased muscle mass and, in trials, reduced fat mass.
Why did Lilly buy Versanis?
Eli Lilly acquired Versanis Bio in July 2023 for up to $1.925 billion to secure bimagrumab as a combination partner for its GLP-1 franchise, positioning the company to lead on body-composition outcomes in obesity.
Is bimagrumab approved for obesity?
No. It is investigational in that setting, with combination trials including BELIEVE still generating data as of 2026.
Are there peptide alternatives to bimagrumab?
Yes — several companies including Regeneron, Scholar Rock, and others are developing myostatin-targeting peptides and small proteins that aim to achieve similar biology with easier manufacturing.
